Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁵, Danting Zhu⁴, David Sandoval Calderon⁴, Proton Rahman⁶ and Denis Poddubnyy⁷, ¹Self Employed 72nd Street Medical Associates, Scarsdale, NY, ²Oregon Health & Science University, Portland, OR, ³CHU Montpellier Montpellier University, Montpellier, France, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Calgary, AB, Canada, ⁶Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…
Abstract Number: 0052 • ACR Convergence 2021
HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
Tejpal Gill¹, Patrick Stauffer¹, Mark Asquith¹, Ted Laderas¹, Tammy Martin², Sean Davin¹, Claire Ramirez¹, Ingrid Lindquist¹, Justine Nguyen¹, stephen Planck¹, Carley Shaut¹, Sarah Diamond¹, James T. Rosenbaum³ and Lisa Karstens¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, and Molecular Microbiology & Immunology, Oregon Health & Sciences University, Portland, OR, ³Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (AxSpA) is immune-mediated inflammatory arthritis, which affects the sacroiliac and spinal joints, and is associated with gut inflammation. Disease pathogenesis is associated…
Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Uta Kiltz¹, Kirsten Hoeper², Ludwig Hammel³, Sebastian Lieb⁴, Andreas Haehle⁴ and Dirk Meyer-Olson⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, ³Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵m&i Fachklinik Bad Pyrmont, Hannover, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0620 • ACR Convergence 2021
Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
krystel aouad¹, Anne Tournadre², Florian LUCASSON¹, Daniel Wendling³, Anna Molto⁴, Bruno Fautrel⁵ and Laure Gossec⁶, ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ²Rheumatology Department, Université Clermont Auvergne, CHU Clermont-Ferrand, INRAE, UNH UMR 1019, Clermont-Ferrand, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Rheumatology department, Cochin hospital, APHP, Paris, France, ⁵Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁶Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Recent data suggest differences between men and women with axial spondyloarthritis (axSpA), in terms of disease activity, disease progression and treatment response [1-3]. Overall,…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0906 • ACR Convergence 2021
Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Floris van Gaalen¹ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Bone loss paradoxically coexists with bone formation in radiographic axial spondyloarthritis (r-axSpA). Assessing bone mineral density (BMD) in r-axSpA poses challenges, namely because of…
Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Désirée van der Heijde¹, Atul Deodhar², Walter Maksymowych³, Joachim Sieper⁴, Filip Van den Bosch⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Ostor⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Yuanyuan Duan¹¹, Alvina D. Chu¹¹ and In-Ho Song¹², ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Oregon Health & Science University, Portland, OR, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁹Montpellier University, Montpellier, France, ¹⁰AbbVie, North Chicago, IL, ¹¹AbbVie Inc, North Chicago, ¹²AbbVie Inc., North Chicago, IL
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Atul Deodhar¹, Ricardo Blanco ², Eva Dokoupilova ³, Marleen van de Sande ⁴, Stephen Hall ⁵, Anna Wiksten ⁶, Brian Porter ⁷, Hanno Richards ⁶, Sibylle Haemmerle ⁶ and Jürgen Braun ⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, ⁴Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, ⁵Monash University, Melbourne, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
Abstract Number: 559 • 2019 ACR/ARP Annual Meeting
Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Manouk de Hooge¹, Floris van Gaalen ², Marleen van de Sande ³, Roberta Ramonda ⁴, Karen Fagerli ⁵, Lennart Jacobsson ⁶, Désirée van der Heijde ², Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University of Padova, Padova, Italy, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of Göteborg, Göteborg, Sweden
Background/Purpose: A recent study in German chronic back pain (CBP) patients (pts) with a suspicion of axial spondyloarthritis (axSpA) report on the performance of, among…
Abstract Number: 595 • 2019 ACR/ARP Annual Meeting
What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study
Walter P. Maksymowych¹, Susanne Juhl Pedersen ², Ulrich Weber ³, Pedro Machado ⁴, Xenofon Baraliakos ⁵, Joachim Sieper ⁶, Stephanie Wichuk ⁷, Denis Poddubnyy ⁸, Martin Rudwaleit ⁹, Désirée van der Heijde ¹⁰, Robert B.M. Landewé ¹¹, Joel Paschke ¹², Mikkel Østergaard ¹³ and Robert Lambert ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ³Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁴University College London, London, United Kingdom, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁷University of Alberta, Edmonton, Canada, ⁸Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁹Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Amsterdam University Medical Center, Amsterdam, Netherlands, ¹²CARE Arthritis, Edmonton, Canada, ¹³Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Active MRI lesions typical of axSpA were reported in 61.6% and 2.2% of axSpA and not-axSpA patients, respectively, from the ASAS classification cohort (ASAS-CC)1.…
Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Marco Garrido-Cumbrera¹, Jordi Gratacós ², Eduardo Collantes ³, Pedro Zarco ⁴, Carlos Sastre ⁵, Sergio Sanz-Gómez ⁶ and Victoria Navarro-Compán ⁷, ¹Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla, ²Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain, Sabadell, Spain, ³Reina Sofia University Hospital, Spain. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain, Cordova, Spain, ⁴Hospital Universitario Fundación Alcorcón, Madrid, Spain, Madrid, Spain, ⁵Novartis Spain, Barcelona, Spain, Barcelona, Spain, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷University Hospital La Paz, IdiPaz, Madrid, Spain
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…
Abstract Number: 1175 • 2019 ACR/ARP Annual Meeting
Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos¹, Philipp Sewerin ², Eugenio de Miguel ³, Christine Kleinmond ⁴, Ankita Shekhawat ⁵, Annette Wiedon ⁶ and Frank Behrens ⁷, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁶Novartis Pharma GmbH, Nürnberg, Germany, ⁷CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds…
Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].